In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)


In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals’ Oxymorphone ER, sold under the brand name Opana ER.  The proposed class alleges that Endo and would-be generic competitor Impax Laboratories entered an illegal reverse payment agreement under which Endo paid Impax more than $100 million to delay launching a less-expensive generic version of Opana ER.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.

Details

Filed on 06/04/2014

Office

685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331

Counsel

Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

1901 Avenue of the Stars Suite 1060
Los Angeles, California 90067
(424) 256-2884
(424) 256-2885

Georgia

3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania